GlassScriptPhysician profile
Tiffany A Steelman
NPI 1073783130
$21,213.32
in general payments reported to CMS, 2019-2025
37 companies · $4,073 in 2025
The $4,073 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,181 · 2022: $4,705 · 2023: $4,193 · 2024: $5,061 · 2025: $4,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,191.49 |
| Education | $135.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,865.39 | 2021-2025 | |
| Amgen INC. | $3,245.94 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $1,806.36 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,649.83 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $1,534.39 | 2021-2025 | Saphnelo, Evusheld |
| Novartis Pharmaceuticals Corporation | $1,354.54 | 2022-2025 | |
| Lilly USA, LLC | $1,136.09 | 2021-2024 | Taltz |
| Genzyme Corporation | $1,074.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,032.68 | 2021-2025 | Benlysta |
| Pfizer INC. | $814.10 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $503.30 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $462.89 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $395.42 | 2021-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $345.14 | 2021-2024 | Lupkynis |
| Radius Health, INC. | $342.40 | 2021-2025 | Tymlos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.79 | 2022-2025 | Ofev, Cyltezo |
| Sobi, INC | $193.12 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $143.59 | 2022-2023 | |
| Organon LLC | $128.21 | 2022-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $125.04 | 2022-2025 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $121.82 | 2022 | |
| Fresenius Kabi USA, LLC | $96.22 | 2023-2024 | Idacio |
| Sandoz INC. | $89.69 | 2024-2025 | Hyrimoz |
| Genentech USA, INC. | $77.77 | 2023-2025 | Actemra |
| Hikma Pharmaceuticals USA | $50.63 | 2022-2023 | Mitigare |
| Kiniksa Pharmaceuticals International, Plc | $46.12 | 2024 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $40.97 | 2022-2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $40.95 | 2022-2024 | Truxima, Simlandi |
| Kyowa Kirin, INC. | $34.14 | 2024 | Crysvita |
| Scilex Pharmaceuticals INC. | $33.30 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $29.93 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $26.20 | 2023 | Arcalyst |
| Tersera Therapeutics LLC | $24.09 | 2025 | Quzyttir |
| Ani Pharmaceuticals, INC. | $19.07 | 2024 | Purified Cortrophin Gel |
| Celltrion USA INC. | $15.95 | 2023 | Yuflyma |
| Neurocrine Biosciences, INC. | $14.53 | 2021 | |
| Redhill Biopharma INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Steelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.